Please use this identifier to cite or link to this item: http://bura.brunel.ac.uk/handle/2438/27188
Title: European Medicines Agency Conflicts With the European Food Safety Authority (EFSA) on Bisphenol A Regulation
Authors: Zoeller, RT
Birnbaum, LS
Collins, TJ
Heindel, J
Hunt, PA
Iguchi, T
Kortenkamp, A
Myers, JP
vom Saal, FS
Sonnenschein, C
Soto, AM
Keywords: bisphenol A;BPA;European Food Safety Authority;European Medicines Agency;endocrine disrupting chemicals;EDCs;risk assessment
Issue Date: 12-Aug-2023
Publisher: Oxford University Press on behalf of the Endocrine Society
Citation: Zoeller, R.T. et al. (2023) 'European Medicines Agency Conflicts With the European Food Safety Authority (EFSA) on Bisphenol A Regulation', Journal of the Endocrine Society, 7 (9), bvad107, pp. 1 - 4. doi: /10.1210/jendso/bvad107.
Abstract: Copyright © The Author(s) 2023. The European Food Safety Authority (EFSA) has revised their estimate of the toxicity of bisphenol A (BPA) and, as a result, have recommended reducing the tolerable daily intake (TDI) by 20 000-fold. This would essentially ban the use of BPA in food packaging such as can liners, plastic food containers, and in consumer products. To come to this conclusion, EFSA used a systematic approach according to a pre-established protocol and included all guideline and nonguideline studies in their analysis. They found that Th-17 immune cells increased with very low exposure to BPA and used this endpoint to revise the TDI to be human health protective. A number of regulatory agencies including the European Medicines Agency (EMA) have written formal disagreements with several elements of EFSA's proposal. The European Commission will now decide whether to accept EFSA's recommendation over the objections of EMA. If the Commission accepts EFSA's recommendation, it will be a landmark action using knowledge acquired through independent scientific studies focused on biomarkers of chronic disease to protect human health. The goal of this Perspective is to clearly articulate the monumental nature of this debate and decision and to explain what is at stake. Our perspective is that the weight of evidence clearly supports EFSA's proposal to reduce the TDI by 20 000-fold.
Description: Data Availability: No original data were generated for this Perspective.
URI: https://bura.brunel.ac.uk/handle/2438/27188
DOI: https://doi.org/10.1210/jendso/bvad107
Other Identifiers: ORCID iDs: R. Thomas Zoeller https://orcid.org/0000-0002-7485-2658; Linda S. Birnbaum https://orcid.org/0000-0001-5429-5658; Terrence J. Collins https://orcid.org/0000-0003-2611-9184; Jerrold Heindel https://orcid.org/0000-0002-0719-6523; Patricia A. Hunt https://orcid.org/0000-0001-9144-1853; Taisen Iguchi https://orcid.org/0000-0002-6020-0704; Andreas Kortenkamp https://orcid.org/0000-0001-9055-9729; John Peterson Myers https://orcid.org/0000-0003-4126-4101; Frederick S vom Saal https://orcid.org/0000-0002-0488-3264; Carlos Sonnenschein https://orcid.org/0000-0003-3475-6423; Ana M. Soto https://orcid.org/0009-0001-0774-3742.
bvad107
Appears in Collections:Dept of Life Sciences Research Papers

Files in This Item:
File Description SizeFormat 
FullText.pdfCopyright © The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.162.16 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons